PTSD is treated most effectively with trauma-focused psychotherapy, sometimes combined with medication. The two FDA-approved medications are sertraline (Zoloft) and paroxetine (Paxil), both antidepressants, but therapy remains the core of treatment. Most people see significant improvement within 12 to 20 sessions of structured therapy, and several well-studied approaches can get the majority of patients to a point where they no longer meet the criteria for a PTSD diagnosis.
Trauma-Focused Therapy: The First-Line Treatment
Three types of therapy have the strongest evidence for PTSD, and all share a common principle: they help you process the traumatic memory rather than avoid it. The specific approach matters less than committing to one of these structured treatments and completing the full course.
Prolonged Exposure (PE) involves gradually and repeatedly revisiting the memory of your trauma in a safe, guided setting, as well as approaching real-world situations you’ve been avoiding. In a large study of U.S. veterans, 73% of those who completed PE responded to treatment. The challenge is that the process of confronting trauma memories is difficult, and dropout rates in that same study reached nearly 56%.
Cognitive Processing Therapy (CPT) focuses less on reliving the memory and more on identifying and changing the beliefs that developed after the trauma, things like “the world is completely unsafe” or “it was my fault.” CPT had a 60% response rate in the same veteran study, with a somewhat lower dropout rate of about 47%. For people who find direct exposure to the memory overwhelming, CPT can feel more manageable.
EMDR (Eye Movement Desensitization and Reprocessing) uses a different approach entirely. While recalling the traumatic memory, you follow a therapist’s guided eye movements or other forms of rhythmic stimulation. The results are striking: in one study at Kaiser Permanente, 100% of people with a single trauma and 77% of those with multiple traumas no longer had PTSD after an average of six sessions. Other trials found 84% to 90% of single-trauma survivors lost their PTSD diagnosis after just three 90-minute sessions. In a head-to-head comparison with the antidepressant fluoxetine (Prozac), 91% of the EMDR group no longer had PTSD at follow-up, compared with 72% in the medication group.
How Long Treatment Takes
According to the American Psychological Association, about 50% of patients recover within 15 to 20 sessions based on self-reported symptoms. Many of the treatments with the best evidence are designed as 12- to 16-week programs with weekly sessions. In practice, some people prefer to continue for 20 to 30 sessions over about six months to achieve fuller remission and build confidence in maintaining their progress.
If you have other conditions alongside PTSD, such as depression, substance use issues, or certain personality difficulties, effective treatment may take longer, often 12 to 18 months. That’s not a sign of failure. It just means the work is more layered.
Medications That Help
Only two medications are FDA-approved specifically for PTSD: sertraline (Zoloft), taken at 50 to 200 mg daily, and paroxetine (Paxil), at 20 to 60 mg daily. Both are SSRIs, a class of antidepressant that increases the availability of serotonin in the brain. The 2023 VA/Department of Defense clinical practice guideline identifies these two as having the strongest evidence from randomized controlled trials.
SSRIs work best when taken at an adequate dose for a long enough period. They don’t eliminate PTSD on their own for most people, but they can reduce the intensity of symptoms like hypervigilance, emotional numbness, and intrusive thoughts enough to make therapy more effective. Many clinicians use medication and therapy together, especially when symptoms are severe.
Medication for Nightmares
Trauma-related nightmares are one of the most disruptive PTSD symptoms, and they don’t always respond to standard SSRIs. Prazosin, a blood pressure medication, is frequently prescribed off-label for this purpose. In one study of children and adolescents, 57% reported a decrease in nightmare frequency at low doses, and 91% continued taking it at discharge, suggesting it was well tolerated. Prazosin works by blocking the adrenaline-related activity that fuels the body’s fight-or-flight response during sleep.
Newer and Less Common Approaches
Stellate Ganglion Block
One of the more surprising treatments gaining attention is the stellate ganglion block (SGB), a quick injection of local anesthetic into a cluster of nerves in the neck that helps regulate the body’s stress response. Across multiple studies, 70% to 83% of treated patients see clinically significant improvement. In a study of 250 active-duty service members, every single participant said they were satisfied with the procedure and would recommend it to a friend with similar symptoms.
The effects appear to build over time. In one dataset, patients showed an average symptom reduction that was modest at one week but nearly tripled by three months, especially when combined with ongoing therapy. An Australian study of 99 civilian patients found similar improvements regardless of the type of trauma experienced. SGB doesn’t replace therapy, but it may lower the nervous system’s baseline reactivity enough to make other treatments more accessible.
Ketamine Infusions
Ketamine, long used as an anesthetic, has shown promise for treatment-resistant PTSD, particularly when other approaches haven’t worked. One study of combat-related PTSD found a 44% reduction in PTSD symptoms and a 50% reduction in depression symptoms. A meta-analysis found that ketamine produced significant improvement over a treatment course of one to four weeks, though a single infusion didn’t produce statistically significant changes at the 24-hour mark. This suggests ketamine works best as a series of treatments rather than a one-time intervention, and it’s typically reserved for people who haven’t responded to at least two medications and a course of therapy.
Transcranial Magnetic Stimulation
TMS uses magnetic pulses to stimulate specific areas of the brain. It’s FDA-cleared for treatment-resistant depression but not yet for PTSD specifically. Still, research shows it outperforms placebo for PTSD symptoms, and in one review of 77 patients with both depression and PTSD, 38% experienced a meaningful reduction in PTSD symptom scores after six weeks of treatment. TMS is noninvasive and generally well tolerated, making it a reasonable option to discuss if standard treatments haven’t been sufficient.
MDMA-Assisted Therapy
MDMA-assisted therapy generated significant excitement after phase 3 trials showed nearly 70% of participants no longer met the criteria for PTSD. The FDA granted it breakthrough therapy status in 2017. However, in 2024, an FDA advisory committee voted against approval, citing concerns about trial design, including problems with blinding (participants could easily tell whether they received MDMA or placebo) and incomplete safety assessments. This treatment is not currently available through standard medical channels, though research continues.
Combining Treatments for Better Results
Most people with PTSD benefit from more than one approach. A common combination is an SSRI to take the edge off symptoms while engaging in trauma-focused therapy like CPT, PE, or EMDR. For people whose nightmares disrupt sleep so badly that they can’t function in daytime therapy sessions, adding prazosin at night can make the whole treatment plan work better. Newer options like SGB or ketamine tend to enter the picture when first-line treatments haven’t provided enough relief, and they work best as additions to therapy rather than replacements for it.
The single most important factor in PTSD treatment is completing a full course of whatever therapy you start. Dropout rates across studies are high, often because the early sessions of trauma-focused therapy feel harder before they feel better. Knowing that upfront, and having a therapist you trust, makes a real difference in outcomes.